Engrail Therapeutics

Biotech · Private

Next-generation GABA receptor subtype-selective modulators for anxiety and sleep disorders

engrailtx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
2 granted · 38 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3131nChroma Bio——
3132ATB Therapeutics——
3133Flux Therapeutics, LLC——
3134Engrail Therapeutics——
3135PHAGEPRO, INC.——
3136HTIC, INC.——
3137Sixal Inc——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 40
  • Deuterated Organic Compounds And Uses Thereofgranted
  • Deuterated Organic Compounds And Uses Thereofapplication
  • Gabaa Receptor Modulator Salts, Particles, And Uses Thereofapplication
  • Deuterated Organic Compounds And Uses Thereofgranted
  • Deuterated Organic Compounds And Uses Thereofapplication
  • Deuterated Organic Compounds And Uses Thereofapplication
  • Crystalline Formsapplication
  • Methods Of Treating Generalized Anxiety Disorderapplication
  • Organic Compounds And Uses Thereofapplication
  • Deuterated Organic Compounds And Uses Thereofapplication
  • Organic Compounds And Uses Thereofapplication
  • Deuterated Organic Compound And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.